Ritlecitinib Tosilate

If approved, Lilly and Incyte’s drug could be the first treatment available for alopecia areata patients aged under 12 years. Image credit: Tada Images / Shutterstock.com. Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata. In the Phase III BRAVE-AA-PEDS trial (NCT05723198) 54.1% and 31% of patients receiving Olumiant (baricitinib) 4mg and 2mg, respectively, achieved successful hair regrowth, defined as 80% or more scalp hair coverage, after 52 weeks. In addition, 41.2% of patients in the high dose cohort and 26.2% in the low dose cohort achieved near-complete scalp hair regrowth, defined as 90% or more scalp hair coverage. Among those with severe disease, 71% in the high-dose group and 58.6% in the low-dose group achieved successful hair regrowth. In regard to eyebrow regrowth, improvements in hair coverage were seen in 64.8% of patients receiving Olumiant 4mg and 27.8% of patients receiving Olumiant 2mg. Meanwhile, 63.3% and 34% taking the 4mg and 2mg tablet, respectively, achieved eyelash regrowth. Based on the Phase III trial, Lilly intends to submit the adolescent data to global regulators for a label update for Olumiant to be used in paediatric patients. If the label is extended to the trial population, it would be a notable development for paediatric patients, as there is just one approved treatment – Pfizer’s Litfulo (ritlecitinib) – for adolescents aged over 12 with severe alopecia areata. Lilly and Incyte’s drug would provide an option for patients between six and 11 years for which there are currently no treatments. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence National Alopecia Areata Foundation (NAAF) president Nicole Friedland said: “For nearly half of the people with severe alopecia areata, the disease starts before adulthood and can progress quickly, significantly impacting patients’ lives. Given the profound burden of this disease, new treatment options are needed for children and adolescents, populations that have been underrepresented for far too long.” The trial enrolled 595 children aged between six to under 18 years with severe alopecia areata, as measured by a Severity of Alopecia Tool (SALT) score of ≥50. The safety profile remained consistent within the paediatric population as that reported in adults. Full data will be presented at the 2025 Fall Clinical Dermatology (FCD) Conference, taking place in Las Vegas between 23 and 26 October. Olumiant is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to Lilly in December 2009. The therapy was approved by the US Food and Drug Administration in 2022 for adult patients with severe alopecia areata . According to GlobalData’s annual sales and consensus forecast, Olumiant’s sales peaked at $1.15bn in 2021; however, sales started to increase again in 2023, with a 2031 sales forecast of $1.09bn. GlobalData is the parent company of Clinical Trials Arena. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

In the span of three weeks, a seven-employee biotech focused on hair loss raised $120 million for Phase 3 trials that will begin next year. Los Angeles-based Pelage Pharmaceuticals announced the Series B on Wednesday morning. Existing investor GV co-led the round with new supporter ARCH Venture Partners, one of the most prolific venture capital firms in the life sciences industry. Backing from the two well-known firms will boost the profile of the small startup, which aims to take on one of the most difficult fields of drug development. GV supported Pelage’s Series A, which initially came in at nearly $17 million in February 2024 and was expanded six months later to include another $14 million. Born out of UCLA basic science research, Pelage aims to activate dormant hair follicle stem cells using an experimental drug called PP405. “People understand the unmet need in hair loss. As we see more and more hair loss with medications like GLP-1s, more awareness of hair loss during perimenopause, menopause, other conditions, that’s going to continue to grow,” Pelage chief medical officer Christina Weng said in an interview. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Brian Miles. You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. “This is a case where we really understand the biological mechanisms of its action. We understand the science. It’s really a drug designed for the 21st century,” she said. The topical treatment PP405 has drummed up attention in recent months as it goes through the clinical trial process, with TIME naming it one of the best inventions of 2025. There’s been little innovation on the hair loss front in recent decades. Now-generic drugs minoxidil and finasteride have long comprised the bulk of the market. Neutraceuticals, low-level light therapy helmets and hair transplantation have also received attention. There are approved treatments for some forms of hair loss caused by autoimmune diseases, including Pfizer’s Litfulo for alopecia areata . Pelage’s small molecule has been through Phase 2a testing in the US. In June, the regenerative medicines company said the once-daily topical helped improve hair density versus placebo. The trial included 78 men and women with androgenetic alopecia. A “diverse range of skin phototypes and hair textures” was included in the randomized trial, Pelage said. Now, equipped with a Series B, Pelage will be able to get all the way through two Phase 3 trials in androgenetic alopecia, which will begin next year, CEO Daniel Gil said in the joint interview with Weng. Gil declined to provide details on the Phase 3 timeline or trial designs. It will likely be at least a couple years before PP405 could make it onto the market since the company will need to collect at least 12 months of safety data on some of the patients as required by the FDA. “Definitely we can understand the impatience on one side, but also it is important to remind folks that running rigorous clinical trials is a process,” Weng said. The biotech is building out its operations to be able to commercialize the topical as an independent company, though an IPO, partnership or acquisition could come along the way, Gil said. AbbVie had the option to buy the biotech, but passed on the opportunity a few years ago, Endpoints previously reported . “A company that has a broad reach in terms of various types of channels, various types of physician practices would be an ideal partner,” Gil said. Dermatologists wouldn’t be the only type of physicians prescribing a medication like PP405, he said. Existing backers also took part in the Series B, including Main Street Advisors, Visionary Ventures and YK Bioventures. Pelage on Wednesday also named GV executive venture partner Cathy Friedman as the chair of its board. ARCH venture partner Rich Heyman is also joining the board. Heyman’s board credentials include ORIC Pharmaceuticals, Enliven Therapeutics and Architect Therapeutics.